MRCP UK EXAMINATIONS

Detailed explanation-1: -Secukinumab is a novel biologic agent specifically targeting interleukin-17 (IL-17) involved in a pathological process. It is a fully human monoclonal antibody. Many clinical trials have demonstrated its efficacy in managing plaque psoriasis in 2015, psoriatic arthritis, and ankylosing spondylitis in 2016.

Detailed explanation-2: -Secukinumab is a drug that reduces the signs and symptoms of psoriatic arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is commonly known as Cosentyx®. It is a type of drug called a biologic.